Jennifer E. Balkus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer E. Balkus has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Raymond Scott McClelland
University of Washington
3 shared publications - Jenell Stewart
Hennepin Healthcare Research Institute, University of Minnesota , Minneapolis, Minnesota
2 shared publications - Christine M. Khosropour
Department of Epidemiology, University of Washington, Seattle, USA
1 shared publication - Daniel Raftery
University of Washington
1 shared publication - Deborah Donnell
Fred Hutchinson Cancer Center
1 shared publication - Elhanan Borenstein
Blavatnik School of Computer Science and AI, Tel Aviv University , Tel Aviv, 6997801
1 shared publication
Latest Publications
- Open Access
Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection
Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria ( Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii , Hoylesella/Prevotella timonensis, and Ureaplasma urealyticum ) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1) Research in context: Evidence before this study: Chlamydia trachomatis (CT) remains the most reported bacterial sexually transmitted infection globally and can lead to serious adverse health outcomes. Previous studies have pointed to an association between the vaginal microbiota composition, particularly the presence of bacterial vaginosis (BV)-associated taxa, and chlamydia susceptibility. However, most studies have been cross-sectional, measuring the microbiome at the time of infection. The few longitudinal studies specifically assessing the microbiome dynamics preceding CT infection have generally been limited by small sample sizes or infrequent sampling. Further, the mechanisms underlying this relationship remain unclear. Added value of this study: In this nested case-control study, we evaluated the vaginal microbiome preceding CT acquisition and compared participants who subsequently acquired infection with matched controls who remained uninfected. We found that women who acquired CT had a significantly higher vaginal microbial diversity in the past 1-2 months, while the CT infection itself did not lead to broad changes in the microbiome, suggesting directionality to this relationship. Participants who acquired CT were >2-fold more likely to have BV by Nugent-Hillier or Amsel criteria at the previous visit. Having a diverse community state type IV was associated with the strongest likelihood of CT acquisition. More specifically, women who acquired CT were more likely to have a microbiome characterized by the depletion of Lactobacillus crispatus and higher abundances of Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii , Hoylesella (Prevotella) timonensis, and Ureaplasma urealyticum. To assess the possible mechanism through which the microbiome influenced CT risk, we measured the cervicovaginal metabolome in a subset of participants. We found that 70% of the effect of the vaginal microbiome on CT acquisition risk could be explained by the metabolome, highlighting the role of bacterial metabolites in CT susceptibility. Overall, by focusing on samples collected prior to infection acquisition, with a short period between visits, our study contributes robust temporal evidence that the vaginal microbiome impacts CT susceptibility rather than simply being correlated, with the presence of CT, with metabolites potentially playing a key role in this relationship. Implications of all the available evidence: Our findings support the concept that the vaginal microbiome is a potentially modifiable risk factor for CT acquisition, with specific BV-associated bacteria, alongside L. crispatus depletion, identified as key modulators of risk. This study is a step towards confirming the directionality of the microbiome-CT infection relationship and establishing potential mechanisms through which the microbiome influences CT risk. These findings, along with previous literature, have the potential to lead to microbiome or metabolite-targeted interventions that would reduce the risk of CT acquisition.
Open AccessCervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection
Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria ( Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii , Hoylesella/Prevotella timonensis, and Ureaplasma urealyticum ) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1) Research in context: Evidence before this study: Chlamydia trachomatis (CT) remains the most reported bacterial sexually transmitted infection globally and can lead to serious adverse health outcomes. Previous studies have pointed to an association between the vaginal microbiota composition, particularly the presence of bacterial vaginosis (BV)-associated taxa, and chlamydia susceptibility. However, most studies have been cross-sectional, measuring the microbiome at the time of infection. The few longitudinal studies specifically assessing the microbiome dynamics preceding CT infection have generally been limited by small sample sizes or infrequent sampling. Further, the mechanisms underlying this relationship remain unclear. Added value of this study: In this nested case-control study, we evaluated the vaginal microbiome preceding CT acquisition and compared participants who subsequently acquired infection with matched controls who remained uninfected. We found that women who acquired CT had a significantly higher vaginal microbial diversity in the past 1-2 months, while the CT infection itself did not lead to broad changes in the microbiome, suggesting directionality to this relationship. Participants who acquired CT were >2-fold more likely to have BV by Nugent-Hillier or Amsel criteria at the previous visit. Having a diverse community state type IV was associated with the strongest likelihood of CT acquisition. More specifically, women who acquired CT were more likely to have a microbiome characterized by the depletion of Lactobacillus crispatus and higher abundances of Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii , Hoylesella (Prevotella) timonensis, and Ureaplasma urealyticum. To assess the possible mechanism through which the microbiome influenced CT risk, we measured the cervicovaginal metabolome in a subset of participants. We found that 70% of the effect of the vaginal microbiome on CT acquisition risk could be explained by the metabolome, highlighting the role of bacterial metabolites in CT susceptibility. Overall, by focusing on samples collected prior to infection acquisition, with a short period between visits, our study contributes robust temporal evidence that the vaginal microbiome impacts CT susceptibility rather than simply being correlated, with the presence of CT, with metabolites potentially playing a key role in this relationship. Implications of all the available evidence: Our findings support the concept that the vaginal microbiome is a potentially modifiable risk factor for CT acquisition, with specific BV-associated bacteria, alongside L. crispatus depletion, identified as key modulators of risk. This study is a step towards confirming the directionality of the microbiome-CT infection relationship and establishing potential mechanisms through which the microbiome influences CT risk. These findings, along with previous literature, have the potential to lead to microbiome or metabolite-targeted interventions that would reduce the risk of CT acquisition.
- Open Access
- 17 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Association Between Vaginal Gram Stain Categories and Cervicitis in Kenyan Women Who Engage in Sex Work
Background: Cervicitis is often caused by Chlamydia trachomatis and Neisseria gonorrhoeae, but remains unexplained in approximately half of cases. Studies examining associations between the vaginal microbiota and cervicitis have produced conflicting results. Methods: This study analyzed data from a cohort of women who engage in sex work in Mombasa, Kenya (2004–2023). Vaginal microbiota was categorized by Nugent criteria as normal (0–3), intermediate (4–6), or bacterial vaginosis (BV, 7–10). Lactobacillus status by culture was classified as none detected, non–H2O2-producing, or H2O2-producing. Cervicitis was defined as >30 polymorphonuclear cells per high-power field. Modified Poisson regression with generalized estimating equations was used to examine associations between Nugent category, Lactobacillus status, and cervicitis. Results: Among 1615 participants (25 322 visits), cervicitis prevalence was 5.8% with normal microbiota, 9.1% with intermediate microbiota (relative risk [RR] 1.39 [95% confidence interval (CI) 1.24–1.56]), and 6.8% with BV (RR 1.14 [95% CI 1.02–1.26]). Cervicitis prevalence also varied by Lactobacillus status: 5.1% with none detected, 8.5% with non–H2O2-producing (RR 1.33 [95% CI 1.18–1.50]), and 11.9% with H2O2-producing Lactobacillus (RR 1.70 [95% CI 1.52–1.90]). Findings remained consistent in multivariable analyses. Conclusions: Intermediate microbiota was associated with the greatest cervicitis risk among Gram stain categories, exceeding both normal microbiota and BV. Unexpectedly, cervicitis risk increased progressively from no Lactobacillus to non–H2O2-producing to H2O2-producing Lactobacillus. These findings suggest that intermediate microbiota may represent a state in which proinflammatory pathways from BV and Lactobacillus-dominated microbiota intersect, potentially driving enhanced neutrophil recruitment. Future studies should test this hypothesis.
- 17 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessAssociation Between Vaginal Gram Stain Categories and Cervicitis in Kenyan Women Who Engage in Sex Work
Background: Cervicitis is often caused by Chlamydia trachomatis and Neisseria gonorrhoeae, but remains unexplained in approximately half of cases. Studies examining associations between the vaginal microbiota and cervicitis have produced conflicting results. Methods: This study analyzed data from a cohort of women who engage in sex work in Mombasa, Kenya (2004–2023). Vaginal microbiota was categorized by Nugent criteria as normal (0–3), intermediate (4–6), or bacterial vaginosis (BV, 7–10). Lactobacillus status by culture was classified as none detected, non–H2O2-producing, or H2O2-producing. Cervicitis was defined as >30 polymorphonuclear cells per high-power field. Modified Poisson regression with generalized estimating equations was used to examine associations between Nugent category, Lactobacillus status, and cervicitis. Results: Among 1615 participants (25 322 visits), cervicitis prevalence was 5.8% with normal microbiota, 9.1% with intermediate microbiota (relative risk [RR] 1.39 [95% confidence interval (CI) 1.24–1.56]), and 6.8% with BV (RR 1.14 [95% CI 1.02–1.26]). Cervicitis prevalence also varied by Lactobacillus status: 5.1% with none detected, 8.5% with non–H2O2-producing (RR 1.33 [95% CI 1.18–1.50]), and 11.9% with H2O2-producing Lactobacillus (RR 1.70 [95% CI 1.52–1.90]). Findings remained consistent in multivariable analyses. Conclusions: Intermediate microbiota was associated with the greatest cervicitis risk among Gram stain categories, exceeding both normal microbiota and BV. Unexpectedly, cervicitis risk increased progressively from no Lactobacillus to non–H2O2-producing to H2O2-producing Lactobacillus. These findings suggest that intermediate microbiota may represent a state in which proinflammatory pathways from BV and Lactobacillus-dominated microbiota intersect, potentially driving enhanced neutrophil recruitment. Future studies should test this hypothesis.
- 9 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , 411-415
Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis
Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54–1.73, P = .9). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.
- 9 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , 411-415
Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis
Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54–1.73, P = .9). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.
- 24 December 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (6) , 325-332
Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013–2016
Objectives: Women who report sex with women are thought to have a lower risk of Chlamydia trachomatis (CT) infection than women who report sex with men only (WSM-only), but comparisons of lifetime burden are limited. Methods: Among 1418 sexually experienced women aged 18 to 39 years participating in the National Health and Nutrition Examination Survey (2013–2016), we estimated weighted CT seroprevalence and Wald-based 95% confidence intervals (CIs) in women who reported ever having sex with a woman (all reported having sex with men also) (WSWM) compared with WSM-only. We defined seropositivity as detection of Pgp3 antibodies and used stratified Poisson regression with robust standard errors to estimate prevalence ratios (PRs). Results: More than half (58.3%) were White non-Hispanic; 16.2% were WSWM. Women who had sex with women and men were somewhat younger (mean, 27.8 vs. 29.0 years; P = 0.07), were younger at sexual debut (mean, 15.6 vs. 17.5 years; P < 0.001), and had more lifetime male sexual partners (mean, 15.9 vs. 6.4; P < 0.001) than WSM-only. Weighted CT seroprevalence was 38.9% (95% CI, 30.4%–47.4%) in WSWM and 28.6% (95% CI, 24.4%–32.9%) in WSM-only. Correlates of higher CT seroprevalence in both groups were Black non-Hispanic race/ethnicity, Hispanic ethnicity, and CT infection in the prior year. Having ≥5 lifetime male partners compared with 1 to 2 partners was associated with higher seroprevalence among WSWM (PR, 4.5; 95% CI, 1.77–11.44) and WSM-only (PR, 2.7; 95% CI, 1.87–3.69). Among WSWM, bisexual identity was associated with lower seroprevalence. Among WSM-only, low income and younger age at sexual debut were associated with higher seroprevalence. Conclusion: Lifetime CT burden was higher in WSWM than WSM-only. Number of lifetime male partners was the strongest predictor of seropositivity for WSWM.
- 24 December 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (6) , 325-332
Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013–2016
Objectives: Women who report sex with women are thought to have a lower risk of Chlamydia trachomatis (CT) infection than women who report sex with men only (WSM-only), but comparisons of lifetime burden are limited. Methods: Among 1418 sexually experienced women aged 18 to 39 years participating in the National Health and Nutrition Examination Survey (2013–2016), we estimated weighted CT seroprevalence and Wald-based 95% confidence intervals (CIs) in women who reported ever having sex with a woman (all reported having sex with men also) (WSWM) compared with WSM-only. We defined seropositivity as detection of Pgp3 antibodies and used stratified Poisson regression with robust standard errors to estimate prevalence ratios (PRs). Results: More than half (58.3%) were White non-Hispanic; 16.2% were WSWM. Women who had sex with women and men were somewhat younger (mean, 27.8 vs. 29.0 years; P = 0.07), were younger at sexual debut (mean, 15.6 vs. 17.5 years; P < 0.001), and had more lifetime male sexual partners (mean, 15.9 vs. 6.4; P < 0.001) than WSM-only. Weighted CT seroprevalence was 38.9% (95% CI, 30.4%–47.4%) in WSWM and 28.6% (95% CI, 24.4%–32.9%) in WSM-only. Correlates of higher CT seroprevalence in both groups were Black non-Hispanic race/ethnicity, Hispanic ethnicity, and CT infection in the prior year. Having ≥5 lifetime male partners compared with 1 to 2 partners was associated with higher seroprevalence among WSWM (PR, 4.5; 95% CI, 1.77–11.44) and WSM-only (PR, 2.7; 95% CI, 1.87–3.69). Among WSWM, bisexual identity was associated with lower seroprevalence. Among WSM-only, low income and younger age at sexual debut were associated with higher seroprevalence. Conclusion: Lifetime CT burden was higher in WSWM than WSM-only. Number of lifetime male partners was the strongest predictor of seropositivity for WSWM.